Henry Wagner, Jr, MD | Authors

Role of Adjuvant Therapy in Resected Stage II/IIIA Non-Small-Cell Lung Cancer

January 01, 2002

The search for effective postoperative adjuvant therapy for patients with resected non-small-cell lung cancer (NSCLC) has been spurred by a high rate of failure after definitive surgery. Except for patients with resected T1, N0, M0 lesions, failure rates exceed 30%. Widespread application of adjuvant therapy has been reined in by a disappointing lack of effectiveness in this setting.

Combined-Modality Therapy of Locally Advanced Non-Small-Cell Lung Cancer

September 01, 1997

Treatment of patients with unresectable stage IIIA and IIIB non-small-cell lung cancer with conventionally-fractionated radiation therapy (ie, total doses of 50 to 60 Gy, using one fraction per day), which was standard